eTheRNA Advances mRNA-Based Melanoma Immunotherapy ECI-006

Source: GEN News, July 2019

eTheRNA immunotherapies plans to advance its mRNA-based immunotherapy candidate for melanoma, ECI-006, to a Phase I/II trial in the third quarter of this year following positive first-in-human data showing immune response in 35% of patients in an adjuvant setting, CEO Steven Powell, PhD, told GEN.

“If we’re successful with that Phase I/II, then we’ll put it in a full-blown Phase II, which in itself could be a pivotal Phase II,” Powell said Tuesday in an interview during the Biotechnology Innovation Association (BIO) 2019 International Convention, held in Philadelphia at the Pennsylvania Convention Center.

Powell spoke two days after eTheRNA presented positive safety and immune response data for ECI-006 at a poster session during the American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31-June 4 in Chicago.